BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance

1h ago, source: Hosted on MSN

Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the ...

Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday

on MSN ago, source:

A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit ...

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

17h ago, source:

Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs ...

BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts

15h ago, source:

Q1 2024 Revenue: Reported at $92.8 million, a 34.9% increase year-over-year, surpassing the estimated $85.6 million. Net Loss ...

BioCryst: Q1 Earnings Snapshot

21h ago, source:

DURHAM, N.C. — DURHAM, N.C. — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $35.4 million in its first quarter. The Durham, North Carolina-based company said it had a loss of 17 ...

BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Tuesday, 5/6/2024

on MSN ago, source:

Stocks that are trading heavily or have substantial price changes on Monday: Paramount Global (PARA), up 32 cents to $13.22. The owner of Paramount Pictures and CBS is reportedly considering a sale to ...

BioCryst Pharma Shares Jump on Strong 1Q

13h ago, source: MarketWatch

Shares of BioCryst Pharmaceuticals rose after the company's first-quarter results were stronger than analysts had forecasted. The stock was up 16% at $5.15 in early trading. Shares are still down 14% ...

BCRX BioCryst Pharmaceuticals, Inc.

3d ago, source: Seeking Alpha

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous ...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3d ago, source: Business Insider

RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 ...

BioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

16h ago, source:

ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million- -Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) - -Pipeline programs, ...

BioCryst Pharmaceuticals Inc BCRX

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3d ago, source: Finanznachrichten

RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 ...